25 Stock Top Picks and 4 ETF (Jan 4-10)

Down cycle in the cyclical nature of the business.A.I. business segment growing.Current share price too expensive to justify investment.Would wait to buy on weakness.

Current share price trading at discount to historical valuation.Excellent brand with established technology.Supports large amount of global payments.Predictable business with growing cash flows.25x P/E justified. 

They are IT consultants and the company is one of their largest positions. It is always buying back stock or distributing some cash to shareholders. Along with increased margins it is at a good valuation, so a good time to buy. It is globally diversified, growing very well by acquisition, and gives a high return…

Successfully transitioned into long reserve life company (Duvernay & Montney).Largest oil wells in Canada.Returning 60% of free cash flow yield to investors.~15 years of high quality inventory.Expecting 100% upside at current share price.Dividend yield ~3% and will also issue special dividends.

(A Top Pick Jan 08/19, Up 13%) We are starting to see a bit of a recovery in the oil price and in the demand. This is an interesting company to watch.

Share buybacks total 35-40% in the last 4-5 years. Likes that. 

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. KEL has strong drilling activity and currently no debt. We have KEL in the growth model portfolio, and we like it for its diversification benefits, being in the oil and gas sector. It is a strong name with a good balance sheet and healthy profit…

Higher interest rates have been a headwind. Likes the yield on ENB (over 7%) and PPL (6.5%).

ETF recommendation? There are a number of them out there. The ones he uses add diversification and are used primarily as a short term trading vehicle for him. He mostly uses SOXX, IGV and FDN.

Brazil is a good choice for broad emerging markets. Geopolitical risk is present with change of government. Long run, Brazil relies on commodities (oil) to fund economy which is risky.

Above $35, has sold all exposure to AMLP. Closer to $30, it is a good place to enter for a trade. Probably will do well buying dips and selling rallies in the near term. Maximum upside is probably $40. Long term, there are some challenges.

The recent inflows into healthcare are based on the new diet drugs like Ozempic. Novo Nordisk and Eli Lilly have benefitted from this trend. These diet drugs are the AI equivalent in healthcare, are blockbusters. 

It reports Tuesday. The CEO is an amazing salesman and he bets he will tell a good story that his movie chain is doing very well.

Has owned shares in the past, but not right now.Company less attractive than in the past.Expensive business costs with inability to generate growing cash flow.Re-investment into theme park business will be beneficial.Concerned about long term prospects for company.Current share price too high to justify investment. 

Luxury hotels. The stock has flatlined due to worries over the coronavirus. They are selling their hotels for management contracts. They are using the cash to buy back stocks. He sees it trading over $100. A well-run business with the family having a lot of stocks. (Analysts’ price target is $86.13)

(A Top Pick Jul 18/22, Up 7%) Expecting further growth of travel.Poor winter conditions impacting share price.Very strong assets with best ski hills in the business.Strong free cash flow with steady dividend.Good value proposition with season's pass.Stock price currently undervalued - good time to buy. 

Smaller cap, so not a big position for her. Grew rapidly during Covid, then hit by series of headwinds. Longer term, still a growth story in the US. Additional costs for new stores, which are mostly coming online later this year. Foot traffic is weakening. Reports next week, she's not expecting upside surprises.

retail He owns retail, but not names like LULU or Nike, but rather defensive ones like this. He sees more weakness in pooer consumers (i.e. Dollar General which plunged recently). HD benefits from the general consumer trade-down of staying in your home longer and fixing it up. The days of consumers being flush with cash…

Cruise lines have all done well because travel is booming. He'd pick this one, but they'll all do well. Q3 is generally their best quarter. Run up a lot already, so may see a pullback after Q3. Pent-up demand might even last into 2024.

Banks reported their Q2 today, but the market reaction to Citi has been weak, a reaction to the consumer's large credit card balances and trading revenue down 13%.

Not best in breed. Primary issue is the Latin American business, where returns were never commensurate with the risk. Acquisitions have proved tricky to integrate. C-suite transitions. He'd be on the sidelines.

Very reliable dividend yield.Good place for steady income.Would recommend for long term hold.

TD vs. SLF vs. CM All of the interest sensitives have been under pressure the last couple of months with rates rising.He favours TD. Tightly regulated oligopoly, and a levered play on the growth of the Canadian, and increasingly US, economy. Surplus of excess capital. 10x earnings. Dominant personal and commercial banking franchise. Good-sized banking…

He target $22.84, much higher than now, and it pays a yield of 7.5%, but where's the growth? They blew up their balance sheet (huge) by buying everything in sight like Direct TV. They also made execution mistakes. It looks cheap, but there's no catalyst to go higher. The telcos have take it on the…

(A Top Pick Jul 31/18, Up 10%) A core name, still likes it and they own it. Industrial gas company, everything from oxygen for hospital to hydrogen needed to refine oil. Made a major acquisition in the U.S in 2016, heavily weigthed to the U.S. Reports in Euros so it uses U.S dollar strength to…

Higher costs thwarted profitability. Move on.

China demand will affect business.Current share price does not justify investment.Hard to predict outcome of business. Cyclical commodity that is hard to earn profits in. 

Has owned this many years. She likes healthcare because of aging demographics. They made a lot of cash during Covid and have used that cash for M&A and R&D. Pays a nice 2.5% dividend. Has an established track record of raising their dividend annually. Trades at a reasonable PE. Lags healthcare, but still likes ABT. 

He's been in business for 30 years, and BBD has never been a good long-term stock. Now, it's in the right space with industrials. The stock is in the bottom of its trading range; if it breaks below that, this will probably return to $30. BBD has a had a decent run this, year the…